Recent Blog Articles
Scoring highly on Alternative Healthy Eating Index lowers risk for many illnesses
Can self-employment promote better cardiovascular health for women?
Why is it so challenging to find a primary care physician?
Harvard Health Ad Watch: A new injection treatment for eczema
3 simple swaps for better heart health
I’m too young to have Alzheimer’s disease or dementia, right?
Asking about guns in houses where your child plays
Behavioral weight loss interventions: Do they work in primary care?
Who needs treatment for ocular hypertension?
The popularity of microdosing of psychedelics: What does the science say?
Guru P. Sonpavde, MD
Guru P. Sonpavde, MD is the director of the bladder cancer program at Dana-Farber Cancer Institute and is on the faculty of Harvard Medical School. He completed his medical oncology fellowship at Indiana University. His primary focus is on clinical trials to develop new drugs and combinations to treat urologic cancers, particularly bladder cancer. He also has led translational projects and developed prognostic classifications and endpoints focused on bladder cancer. He is a member of the Genitourinary Committee of Southwest Oncology Group and the Bladder Cancer Task Force of the National Cancer Institute Genitourinary Steering Committee.